OncoTherapy Science, Inc. (FRA:30O)

Germany flag Germany · Delayed Price · Currency is EUR
0.0965
+0.0055 (6.04%)
At close: Dec 4, 2025
-44.86%
Market Cap 41.28M
Revenue (ttm) 5.51M
Net Income (ttm) -4.75M
Shares Out n/a
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open 0.0965
Previous Close 0.0910
Day's Range 0.0965 - 0.0965
52-Week Range 0.0855 - 0.2080
Beta n/a
RSI 46.57
Earnings Date Feb 6, 2026

About OncoTherapy Science

OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stag... [Read more]

Industry Commercial Physical and Biological Research
Founded 2001
Employees 47
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 30O
Full Company Profile

Financial Performance

In 2024, OncoTherapy Science's revenue was 750.00 million, an increase of 22.95% compared to the previous year's 610.00 million. Losses were -815.00 million, -36.72% less than in 2023.

Financial numbers in JPY Financial Statements

News

There is no news available yet.